Karo Bio Ab

Kancera Ab

Karo Pharma Ab

Lars Krüger

Joakim Löfstedt

Kristin Hammer

Mattias Jönsson

Xiongyu Wu

Jan Vågberg

Konrad Koehler

Neeraj Garg

Elisabeth Olsson

Aiping Cheng

Lars Hagberg

Katarina Färnegårdh

Eva Koch

Daniel Nöteberg

Johan Schultz

Joakim LÖFSTEDT

A compound of formula (Ia) or (Ib) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of a histone deacetylase, and as such is useful in therapy, e.g. in the treatment of autoimmune disorders, mental disorders, neurodegenerative disorders, and hyperproliferative disorders.

Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity

A compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the compound. The compound is useful in therapy, for the treatment of disorders mediated by HDAC6, such as autoimmune disorders, neurodegenerative disorders and hyperproliferative disorders, such as cancer. 

Benzimidazole derivates useful as inhibitors of mammalian histone deacetylase activity

Compounds of formula (I) or a pharmaceutically acceptable ester, amide, carbamate or salt thereof, including a salt of such an ester, amide or carbamate in which Rto Rhave meanings as defined in the Specification, are useful as estrogen receptor ligands. 

Estrogen receptor ligands

The invention provides a compound of formula (I) wherein G is a pyrazole ring as defined in the specification and R, R, Rand Rare as defined in the specification; or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. The invention also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity. 

Substituted pyrazoles as estrogen receptor ligands

Growing community of inventors

Huddinge, Sweden

Lars Krüger